Biotricity Inc. reported its second‑quarter fiscal 2026 results, showing revenue of $3.9 million—an increase of 19 % year‑over‑year—driven by a 20 % rise in recurring technology‑as‑a‑service fees that now account for 88.7 % of total revenue. The company’s flagship Biocore Pro cardiac monitoring device continued to gain traction, contributing a 15 % lift in device sales and reinforcing the company’s shift toward high‑margin, subscription‑based revenue streams.
Gross margin expanded to 81.9 %, up from 75.3 % in the same quarter last year. The improvement reflects the growing mix of technology‑fee revenue, which carries lower variable costs, and the impact of AI‑driven automation that has reduced support and maintenance expenses. The margin expansion also signals that the company is successfully scaling its operations while maintaining pricing power in a competitive market.
Net loss narrowed to $0.77 million, a 53.3 % improvement versus the $1.66 million loss reported in Q1 fiscal 2026. The reduction in loss is largely attributable to the higher gross margin and disciplined operating expenses, which were offset by a modest increase in research and development spend to accelerate the next‑generation product pipeline. The company also reported positive EBITDA for the second consecutive quarter, underscoring the effectiveness of its cost‑control initiatives.
Management highlighted the role of AI automation in driving operational efficiency and emphasized continued focus on expanding the Biocore Pro platform into new diagnostic verticals such as sleep and pulmonology. CEO Dr. Waqaas Al‑Siddiq noted that the company’s “scalable model” is validated by the rapid adoption of its devices and the launch of large‑scale monitoring pilots across leading hospital networks. These developments position Biotricity to capture growing demand for remote cardiac monitoring and related services.
Investors responded favorably to the results, citing the company’s revenue growth, margin expansion, and improved profitability as key drivers of confidence. The positive outlook is reinforced by the company’s strategic emphasis on recurring revenue, AI‑enabled operations, and geographic expansion, which collectively suggest a trajectory toward sustainable profitability.
The company’s financial health continues to improve, with a stronger balance sheet and a clear path to profitability as it scales its technology platform and expands into adjacent markets. The results reinforce Biotricity’s competitive positioning in the connected‑health space and support its long‑term growth strategy.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.